ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 927,62
0,00%
Dow Jones
44 424,25
-0,32%
DAX
21 394,93
-0,11%
Brent Oil
77,095
-0,12%
Bitcoin
99 000,79
-5,41%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Neurocrine Biosciences Inc (NBIX) Cours

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NBIX)

NASDAQ
148,73
1,15
(0,78%)
Fermé 27 Janvier 10:00PM
Retardé de 15 minutes
148,73
0,03
(0,02%)
Après les heures de négociation: 10:28PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
148,73
Prix Achat
146,50
Prix Vente
151,00
Volume échangé
946 019
145,9697 Fourchette du Jour 149,18
110,95 Plage de 52 semaines 157,9799
Cap du marché
15,058B
Clôture Veille
147,58
Ouverture
146,40
Dernière Transaction
1
@
146.5
Dernière heure de transaction
Volume financier
US$ 140 381 178
VWAP
148,3915
Volume moyen (3 m)
970 657
Actions en circulation
101 246 911
Rendement du Dividende
-
Ratio Cours sur Bénéfices
60,30
Bénéfice par action (BPA)
2,47
Chiffre d'affairess
1,89B
Bénéfice net
249,7M

À propos de Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is a... Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.neurocrine.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Neurocrine Biosciences Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker NBIX. Le dernier cours de clôture d'Neurocrine Biosciences était de US$147,58. Au cours de la dernière année, les actions de Neurocrine Biosciences ont été négociées dans une fourchette de prix de US$ 110,95 à US$ 157,9799.

Neurocrine Biosciences compte actuellement 101 246 911 actions en circulation. La capitalisation boursière d'Neurocrine Biosciences est de US$14,94 milliard. Neurocrine Biosciences a un ratio cours/bénéfice (ratio PE) de 60.30.

Flux d'options Neurocrine Biosciences (NBIX)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

149k

Calls / Puts

100,00%

Ach. / Vent.

100,00%

OTM / ITM

0,00%

Sweeps Ratio

0,00%

NBIX Dernières nouvelles

Plus de nouvelles

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device PR Newswire SAN DIEGO, Jan. 23, 2025 SAN DIEGO, Jan. 23, 2025 /PRNewswire/...

23 Janvier 2025
PR Newswire (US)

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism PR Newswire SAN DIEGO, Jan. 21, 2025...

21 Janvier 2025
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

17 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

15 Janvier 2025
Edgar (US Regulatory)

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism PR Newswire SAN...

08 Janvier 2025
PR Newswire (US)

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 6, 2025 SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc...

06 Janvier 2025
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

03 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

31 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

20 Décembre 2024
Edgar (US Regulatory)

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, Dec. 20, 2024...

20 Décembre 2024
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
15.884.11620581029142.85148.73141.57943972145.18960962CS
49.6756.95767861637139.055148.73136.01894625140.51922496CS
1228.2123.4069034185120.52148.73115.34970657131.31029853CS
263.862.66445778974144.87157.9799110.95959095129.32850592CS
527.555.34778297209141.18157.9799110.95888629133.19706423CS
15674.3399.905913978574.4157.979972.28799733114.72920841CS
26046.5645.5711069786102.17157.979971.875819295108.48366964CS

NBIX - Frequently Asked Questions (FAQ)

What is the current Neurocrine Biosciences share price?
The current share price of Neurocrine Biosciences is US$ 148,73
How many Neurocrine Biosciences shares are in issue?
Neurocrine Biosciences has 101 246 911 shares in issue
What is the market cap of Neurocrine Biosciences?
The market capitalisation of Neurocrine Biosciences is USD 14,94B
What is the 1 year trading range for Neurocrine Biosciences share price?
Neurocrine Biosciences has traded in the range of US$ 110,95 to US$ 157,9799 during the past year
What is the PE ratio of Neurocrine Biosciences?
The price to earnings ratio of Neurocrine Biosciences is 60,3
What is the cash to sales ratio of Neurocrine Biosciences?
The cash to sales ratio of Neurocrine Biosciences is 7,98
What is the reporting currency for Neurocrine Biosciences?
Neurocrine Biosciences reports financial results in USD
What is the latest annual turnover for Neurocrine Biosciences?
The latest annual turnover of Neurocrine Biosciences is USD 1,89B
What is the latest annual profit for Neurocrine Biosciences?
The latest annual profit of Neurocrine Biosciences is USD 249,7M
What is the registered address of Neurocrine Biosciences?
The registered address for Neurocrine Biosciences is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Neurocrine Biosciences website address?
The website address for Neurocrine Biosciences is www.neurocrine.com
Which industry sector does Neurocrine Biosciences operate in?
Neurocrine Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
EVAXEvaxion Biotech AS
US$ 5,99
(64,56%)
55,41M
ELABPMGC Holdings Inc
US$ 3,0901
(56,07%)
76,48M
PCLAPicoCELA Inc
US$ 4,60
(49,35%)
3,75M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
GODNUGolden Star Acquisition Corporation
US$ 3,11
(-75,82%)
17,51k
GODNGolden Star Acquisition Corporation
US$ 2,93
(-65,67%)
902,76k
NXTTNext Technology Holding Inc
US$ 1,37
(-54,93%)
2,56M
SGLYSingularity Future Technology Ltd
US$ 1,625
(-38,45%)
917,77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90,11
(-38,07%)
8
ACONAclarion Inc
US$ 0,0557
(28,94%)
811,91M
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
RIMEAlgorhythm Holdings Inc
US$ 0,0357
(4,69%)
284,97M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
NVDANVIDIA Corporation
US$ 142,62
(-3,12%)
232,88M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
NBIX
Neurocrine Biosciences
BIT
BS26
Exchange Traded Fund Ivz...
NYSE
QNGY
Quanergy Systems
BIT
P1Z1S2
NLBNPIT1Z1S2 20991231 11...
BIT
SUAS
Exchange Traded
BIT
UIJ139
Unicredit Bank
BIT
UI818C
Unicredit Bank
AQSE
VDEV.GB
Vanguard Ftse Developed ...
BIT
UC4PPK
Unicredit Bank
NYSE
EAI
Entergy Arkansas
BIT
GS0121
Goldman Sachs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés